246 related articles for article (PubMed ID: 34712933)
1. Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B.
Moctezuma-Velázquez C; Lewis S; Lee K; Amodeo S; Llovet JM; Schwartz M; Abraldes JG; Villanueva A
JHEP Rep; 2021 Dec; 3(6):100364. PubMed ID: 34712933
[TBL] [Abstract][Full Text] [Related]
2. Radiological diagnosis of hepatocellular carcinoma does not preclude biopsy before treatment.
Brusset B; Jacquemin M; Teyssier Y; Roth GS; Sturm N; Roustit M; Bône A; Ghelfi J; Costentin CE; Decaens T
JHEP Rep; 2024 Jan; 6(1):100957. PubMed ID: 38234407
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the accuracy of AASLD and LI-RADS criteria for the non-invasive diagnosis of HCC smaller than 3 cm.
Ronot M; Fouque O; Esvan M; Lebigot J; Aubé C; Vilgrain V
J Hepatol; 2018 Apr; 68(4):715-723. PubMed ID: 29274407
[TBL] [Abstract][Full Text] [Related]
4. EASL versus LI-RADS: Intra-individual comparison of MRI with extracellular contrast and gadoxetic acid for diagnosis of small HCC.
Min JH; Kim JM; Kim YK; Kim H; Cha DI; Kang TW; Choi GS; Choi SY; Ahn S
Liver Int; 2021 Dec; 41(12):2986-2996. PubMed ID: 34242468
[TBL] [Abstract][Full Text] [Related]
5. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic value of contrast-enhanced ultrasound LI-RADS for hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis B.
Yang D; Hu H; Li R; Tang CL; Ma KS; Guo DY
Abdom Radiol (NY); 2022 Feb; 47(2):630-639. PubMed ID: 34910237
[TBL] [Abstract][Full Text] [Related]
7. Comparison of LI-RADS with other non-invasive liver MRI criteria and radiological opinion for diagnosing hepatocellular carcinoma in cirrhotic livers using gadoxetic acid with histopathological explant correlation.
Clarke CGD; Albazaz R; Smith CR; Rowe I; Treanor D; Wyatt JI; Sheridan MB; Guthrie JA
Clin Radiol; 2021 May; 76(5):333-341. PubMed ID: 33461746
[TBL] [Abstract][Full Text] [Related]
8. Comparison of international guidelines for diagnosis of hepatocellular carcinoma and implications for transplant allocation in liver transplantation candidates with gadoxetic acid enhanced liver MRI versus contrast enhanced CT: a prospective study with liver explant histopathological correlation.
Odedra D; Jandaghi AB; Bhayana R; Elbanna KY; Espin-Garcia O; Fischer SE; Ghanekar A; Sapisochin G; Jhaveri KS
Cancer Imaging; 2022 Oct; 22(1):55. PubMed ID: 36195953
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.
Kierans AS; Song C; Gavlin A; Roudenko A; Lu L; Askin G; Hecht EM
AJR Am J Roentgenol; 2020 Nov; 215(5):1085-1092. PubMed ID: 32877248
[No Abstract] [Full Text] [Related]
10. Diagnostic Performance of the 2018 EASL vs. LI-RADS for Hepatocellular Carcinoma Using CT and MRI: A Systematic Review and Meta-Analysis of Comparative Studies.
Shin J; Lee S; Yoon JK; Roh YH
J Magn Reson Imaging; 2023 Dec; 58(6):1942-1950. PubMed ID: 37010244
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
[TBL] [Abstract][Full Text] [Related]
12. Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS.
Cannella R; Dioguardi Burgio M; Beaufrère A; Trapani L; Paradis V; Hobeika C; Cauchy F; Bouattour M; Vilgrain V; Sartoris R; Ronot M
JHEP Rep; 2021 Dec; 3(6):100380. PubMed ID: 34825155
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
[TBL] [Abstract][Full Text] [Related]
14. Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
Lee S; Kim MJ; Kim SS; Shin H; Kim DY; Choi JY; Park MS; Mitchell DG
Hepatol Int; 2020 Jan; 14(1):70-79. PubMed ID: 31802388
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018.
Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
Korean J Radiol; 2021 Jul; 22(7):1066-1076. PubMed ID: 33739633
[TBL] [Abstract][Full Text] [Related]
16. Contrast-enhanced ultrasound algorithm (ACR CEUS LI-RADSv 2017)- a valuable tool for the noninvasive diagnosis of hepatocellular carcinoma in patients with chronic liver disease.
Ghiuchici AM; Dănilă M; Popescu A; Șirli R; Moga T; Topan M; Bende F; Sporea I
Med Ultrason; 2021 Nov; 23(4):383-389. PubMed ID: 33793696
[TBL] [Abstract][Full Text] [Related]
17. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging.
De Gaetano AM; Catalano M; Pompili M; Marini MG; Rodríguez Carnero P; Gullì C; Infante A; Iezzi R; Ponziani FR; Cerrito L; Marrone G; Giuliante F; Ardito F; Rapaccini GL; Vecchio FM; Giraldi L; Manfredi R;
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7786-7801. PubMed ID: 31599447
[TBL] [Abstract][Full Text] [Related]
18. Use of CEUS LI-RADS for the Accurate Diagnosis of Nodules in Patients at Risk for Hepatocellular Carcinoma: A Validation Study.
Makoyeva A; Kim TK; Jang HJ; Medellin A; Wilson SR
Radiol Imaging Cancer; 2020 Mar; 2(2):e190014. PubMed ID: 33778701
[TBL] [Abstract][Full Text] [Related]
19. Man or machine? Prospective comparison of the version 2018 EASL, LI-RADS criteria and a radiomics model to diagnose hepatocellular carcinoma.
Jiang H; Liu X; Chen J; Wei Y; Lee JM; Cao L; Wu Y; Duan T; Li X; Ma L; Song B
Cancer Imaging; 2019 Dec; 19(1):84. PubMed ID: 31806050
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection.
Shao S; Liang Y; Kuang S; Chen J; Shan Q; Yang H; Zhang Y; Wang B; J Fowler K; Wang J; B Sirlin C
Bosn J Basic Med Sci; 2020 Aug; 20(3):401-410. PubMed ID: 31999940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
